Analysts/Institutional Investor Meet/Con. Call Updates

August 03, 2026 The Manager (CRD) The Manager –Listing Department The BSE Limited National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Fort, Bandra-Kurla Complex, Bandra (East) Mumbai- 400001 Mumbai - 400 051 Scrip Code: 530117 Symbol: PRIVISCL Dear Sir / Madam, Ref: Letter dated July 31, 2026, providing Audio link of the Analyst / Investors Meet Sub: Transcript of Analyst/ Investors Meet held on Friday, July 31, 2026 In addition to Audio Link shared via letter dated July 31, 2026, please also find enclosed the transcript of the Analysts/Investors Call on the Audited Standalone and Consolidated Financial Results of Privi Speciality Chemicals Limited for the quarter ended June 30, 2026, held on July 30, 2026 You are requested to kindly take the same on record. Thanking you. Yours Sincerely, For Privi Speciality Chemicals Limited Ashwini Saumil Shah Company Secretary Encl: As above “Privi Speciality Chemicals Limited Q1 FY27 Earnings Conference Call” July 31, 2026 MANAGEMENT: MR.MAHESH BABANI – CHAIRMAN AND MANAGING DIRECTOR MR.R.S.RAJAN – PRESIDENT MR.NARAYAN S.IYER – CHIEF FINANCIAL OFFICER MS.ASHWINI SHAH – COMPANY SECRETARY AND COMPLIANCE OFFICER MR.SANJEEV PATIL – EXECUTIVE VICE PRESIDENT, STRATEGY AND BIOTECHNOLOGY Page 1 of 16 Privi Speciality Chemicals Limited July 31, 2026 Moderator: Ladies and gentlemen, good day and welcome to the Privi Speciality Chemicals Limited Q1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions at the end of today's presentation. Should you need assistance during the conference call, please signal an operator by pressing ‘*’ then ‘0’ on your touchtone phone. Please note that this conference is being recorded. From the management, we have with us Mr. Mahesh Babani – Chairman and Managing Director of the company; Mr. R. S. Rajan – President of the company, Mr. Narayan S. Iyer – Chief Financial Officer of the company; Mr. Sanjeev Patil – Executive Vice President (Strategy and Biotechnology), Ms. Ashwini Shah – Company Secretary and Compliance Officer. And before we begin the conference call, I would like to mention that some of the statements made during the course of today's conference call may contain forward-looking statements about the company, which are based on beliefs, opinion and expectations of the company as on the date of this call. These statements are not the guarantees of future performance and may involve risks and uncertainties that are difficult to predict. I would now like to hand the conference over to Mr. Mahesh Babani – Chairman and Managing Director of Privi Speciality Chemicals. Thank you and over to you, sir. Mahesh Babani: Thank you. Good afternoon, everyone, and thank you for joining Privi Speciality Chemicals Q1 FY 27 Earnings Conference Call. Q1 FY27 marks another important year in Privi’s growth journey. Our focus remains on executing the expansion projects currently underway, strengthening our specialty product portfolio and further building on the long-standing relationship with customers across the globe. The first quarter reflects a very positive start of the year. Our business continues to benefit from the confidence that global customers place in Privi’s manufacturing capabilities and ability to consistently deliver high-quality products. These enduring customer relationships remain one of our key strengths and continue to support our growth across existing products and new business opportunities. With that, I will now request Sanjeev to take you through the operational highlights of the quarter. Sanjeev Patil: Thank you, sir. Good afternoon everyone. Q1 FY27 has been an encouraging start for the year. During the quarter, company reported revenue of Rs. 666 crore, which is reflecting growth of 19.22% year-on-year, supported by healthy demand across both domestic and international markets. Page 2 of 16 Privi Speciality Chemicals Limited July 31, 2026 Despite adverse global headwinds, demand across the fragrance and flavor value chain remained healthy during the quarter. Global customers continue to focus on supply chain diversification and dependable sourcing, while premiumization and innovation across end-to-end use category continue to support demand for specialty aroma ingredients. These structural trends continue to create opportunities for companies with differentiated manufacturing capabilities, diversified sourcing and strong execution capabilities like our company. Operationally, we continued to execute our expansion roadmap during the quarter. The balanced manufacturing base together with our sourcing flexibility across both processes remains an important competitive advantage, enabling us to optimize raw material procurement while ensuring reliable supplies to our global customer base. Our product development pipeline also continues to progress well. We are advancing several high value specialty molecules like Maltol, Ethyl Maltol, Ethylene brassylate, Musk T as we call it, Cyclopentanone. Further, our long-term roadmap emphasizes introduction of 10 advanced specialty products as part of our Phase-2 and Phase-3 expansion program. The joint venture PRIGIV also continued to make steady progress during the quarter. Following the achievement of profitability in Q4 FY26, we remain focused on scaling the business further, supported by planned capacity additions with infusion of additional equity, as you all know, and development of high value specialty molecules further. Operationally, our supply chain remains stable despite the evolving global geopolitical environment. Our diversified sourcing strategy, particularly our backward integration into pine chemistry and global raw material procurement network continues to provide resilience and flexibility in managing input availability and customer deliveries. This has enabled us to consistently meet customer requirements across key markets. Looking ahead, our focus remains on disciplined execution of ongoing expansion program, progressing the specialty product pipeline, and further enhancing our position as a preferred global partner in aroma and specialty chemicals. With that, I now hand over to Mr. Narayan Iyer, our CFO, to take you further into the financial details. Thank you. Narayan S. Iyer: Good evening to all. Thank you, Sanjeev. Thank you, Mahesh, and a very, very warm welcome to all of you. We are pleased to report and start the Financial Year ‘26-'27 with strong financial performance delivered in a dynamic and evolving macro environment. Our performance reflects strong execution, disciplined cost management, and continued strength of our diversified product portfolio. Our performance for the quarter highlights our ability to protect profitability across cycles and reinforces our confidence in the structural strength of our operations and the organization. Page 3 of 16 Privi Speciality Chemicals Limited July 31, 2026 Key highlights for the quarter which has gone by: We reported strong growth despite subdued market. A 19.22% revenue growth was reported during this quarter on a year-on-year basis comparison. We delivered around 25% margins consistently now across the last nine quarters. The EBITDA margins are expected to sustain at a (+20%) driven by the operational efficiencies and improved product mix and increased capacities going to come forward in the near future and in the coming years. Our JV with PRIGIV is progressing as per expectations and we expect meaningful contributions to keep coming ahead. On the CAPEX update: As Sanjeev mentioned, our Phase-1 of production capacity expansion is progressing as planned and is expected to be commercialized shortly. This shall increase our production capacity from 48,000 to 54,000 metric tons of all our existing products. Phase-2 and 3 of the multi-specialty aroma chemicals project is also progressing as plan [Showing first 8,000 characters — download PDF for full document]